{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Jazz Pharmaceuticals plc"},"Symbol":{"label":"Symbol","value":"JAZZ"},"Address":{"label":"Address","value":"WATERLOO ROAD,FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7, Ireland"},"Phone":{"label":"Phone","value":"+353 16347800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy."},"CompanyUrl":{"label":"Company Url","value":"https://www.jazzpharmaceuticals.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bruce C. Cozadd","title":"Chairman & Chief Executive Officer"},{"name":"Liz Henderson","title":"Senior Vice President-Technical Operations"},{"name":"Renée D. Galá","title":"President & Chief Operating Officer"},{"name":"Robert Iannone","title":"Executive VP-Global Head Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}